Impact on toxin production and cell morphology inClostridium difficileby ridinilazole (SMT19969), a novel treatment forC. difficileinfection

A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections

(2015) Richard Vickers et al.   BMC INFECTIOUS DISEASES

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI

(2015) A. Sattar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile

(2015) D. Corbett et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Burden of Clostridium difficile Infection in the United States

(2015) Fernanda C. Lessa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of Toxemia in Patients with Clostridium difficile Infection

(2015) Hua Yu et al.   PLoS One

In VivoAssessment of SMT19969 in a Hamster Model of Clostridium difficile Infection

(2014) William Weiss et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model

(2014) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Identification and Characterization of a Gene Cluster Required for Proper Rod Shape, Cell Division, and Pathogenesis in Clostridium difficile

(2014) E. M. Ransom et al.   JOURNAL OF BACTERIOLOGY

ComparativeIn VitroActivities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates

(2013) Ellie J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ComparativeIn VitroActivities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence

(2013) Ellie J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Markers of Intestinal Inflammation, Not Bacterial Burden, Correlate With Clinical Outcomes in Clostridium difficile Infection

(2013) Rana E. El Feghaly et al.   CLINICAL INFECTIOUS DISEASES

Intestinal Inflammatory Biomarkers and Outcome in Pediatric Clostridium difficile Infections

(2013) Rana E. El Feghaly et al.   JOURNAL OF PEDIATRICS

Diverse Sources of C. difficile Infection Identified on Whole-Genome Sequencing

(2013) David W. Eyre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial Management

(2012) D. W. Eyre et al.   CLINICAL INFECTIOUS DISEASES

Burden of Clostridium difficile on the Healthcare System

(2012) Erik R. Dubberke et al.   CLINICAL INFECTIOUS DISEASES

Can we identify patients at high risk of recurrent Clostridium difficile infection?

(2012) C.P. Kelly   CLINICAL MICROBIOLOGY AND INFECTION

Fidaxomicin inhibits toxin production in Clostridium difficile

(2012) F. Babakhani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Clostridium difficile Toxins: Mediators of Inflammation

(2012) Aimee Shen   Journal of Innate Immunity

Systemic Dissemination of Clostridium difficile Toxins A and B Is Associated With Severe, Fatal Disease in Animal Models

(2011) Jennifer Steele et al.   JOURNAL OF INFECTIOUS DISEASES

A Common Polymorphism in the Interleukin‐8 Gene Promoter Is Associated with an Increased Risk for RecurrentClostridium difficileInfection

(2010) Kevin W. Garey et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

(2010) Stuart H. Cohen et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Economic healthcare costs of Clostridium difficile infection: a systematic review

(2010) S.S. Ghantoji et al.   JOURNAL OF HOSPITAL INFECTION

Cross-kingdom interactions:Candida albicansand bacteria

(2009) Mark E. Shirtliff et al.   FEMS MICROBIOLOGY LETTERS

Clostridium difficile— More Difficult Than Ever

(2008) Ciarán P. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE